883
Views
62
CrossRef citations to date
0
Altmetric
Review Article

Mammalian TOR signaling to the AGC kinases

&
Pages 527-547 | Received 18 Jun 2011, Accepted 24 Aug 2011, Published online: 10 Oct 2011

References

  • Abe Y, Yoon SO, Kubota K, Mendoza MC, Gygi SP, Blenis J. 2009. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem 284:14939–14948.
  • Abraham RT. 2004. PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways. DNA Repair (Amst) 3:883–887.
  • Acosta-Jaquez HA, Keller JA, Foster KG, Ekim B, Soliman GA, Feener EP, Ballif BA, Fingar DC. 2009. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol 29:4308–4324.
  • Akcakanat A, Singh G, Hung MC, Meric-Bernstam F. 2007. Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun 362:330–333.
  • Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. 1996a. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551.
  • Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. 1996b. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 399:333–338.
  • Alessi DR, Pearce LR, García-Martínez JM. 2009. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2:pe27.
  • Alessi DR, Sakamoto K, Bayascas JR. 2006. LKB1-dependent signaling pathways. Annu Rev Biochem 75:137–163.
  • Ali SM, Sabatini DM. 2005. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem 280:19445–19448.
  • Ananthanarayanan B, Fosbrink M, Rahdar M, Zhang J. 2007. Live-cell molecular analysis of Akt activation reveals roles for activation loop phosphorylation. J Biol Chem 282:36634–36641.
  • Armstrong JL, Bonavaud SM, Toole BJ, Yeaman SJ. 2001. Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J Biol Chem 276:952–956.
  • Balendran A, Casamayor A, Deak M, Paterson A, Gaffney P, Currie R, Downes CP, Alessi DR. 1999a. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 9:393–404.
  • Balendran A, Currie R, Armstrong CG, Avruch J, Alessi DR. 1999b. Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 274:37400–37406.
  • Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP. 2005. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci USA 102:667–672.
  • Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. 2002. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277:39858–39866.
  • Behn-Krappa A, Newton AC. 1999. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr Biol 9:728–737.
  • Belham C, Comb MJ, Avruch J. 2001. Identification of the NIMA family kinases NEK6/7 as regulators of the p70 ribosomal S6 kinase. Curr Biol 11:1155–1167.
  • Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P. 1998. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17:313–325.
  • Belova L, Brickley DR, Ky B, Sharma SK, Conzen SD. 2008. Hsp90 regulates the phosphorylation and activity of serum- and glucocorticoid-regulated kinase-1. J Biol Chem 283:18821–18831.
  • Bentzinger CF, Romanino K, Cloëtta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M, Zorzato F, Hall MN, Rüegg MA. 2008. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 8:411–424.
  • Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14:159–169.
  • Biondi RM, Kieloch A, Currie RA, Deak M, Alessi DR. 2001. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 20:4380–4390.
  • Biondi RM, Nebreda AR. 2003. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J 372:1–13.
  • Bogusz AM, Brickley DR, Pew T, Conzen SD. 2006. A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway. FEBS J 273:2913–2928.
  • Bornancin F, Parker PJ. 1996. Phosphorylation of threonine 638 critically controls the dephosphorylation and inactivation of protein kinase Calpha. Curr Biol 6:1114–1123.
  • Bosotti R, Isacchi A, Sonnhammer EL. 2000. FAT: a novel domain in PIK-related kinases. Trends Biochem Sci 25:225–227.
  • Boulbes D, Chen CH, Shaikenov T, Agarwal NK, Peterson TR, Addona TA, Keshishian H, Carr SA, Magnuson MA, Sabatini DM, Sarbassov dos D. 2010. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res 8:896–906.
  • Bozulic L, Surucu B, Hynx D, Hemmings BA. 2008. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30:203–213.
  • Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893–2904.
  • Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95:1432–1437.
  • Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL. 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173:279–289.
  • Cameron AJ, De Rycker M, Calleja V, Alcor D, Kjaer S, Kostelecky B, Saurin A, Faisal A, Laguerre M, Hemmings BA, McDonald N, Larijani B, Parker PJ. 2007. Protein kinases, from B to C. Biochem Soc Trans 35:1013–1017.
  • Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. 2010. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 107:12469–12474.
  • Carrière A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP. 2008. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18:1269–1277.
  • Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P, Fingar DC, Roux PP. 2011. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286:567–577.
  • Cheatham L, Monfar M, Chou MM, Blenis J. 1995. Structural and functional analysis of pp70S6k. Proc Natl Acad Sci USA 92:11696–11700.
  • Chen CH, Shaikenov T, Peterson TR, Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK, Sarbassov dos D. 2011. ER stress inhibits mTORC2 and Akt signaling through GSK-3ß-mediated phosphorylation of rictor. Sci Signal 4:ra10.
  • Chen W, Chen Y, Xu BE, Juang YC, Stippec S, Zhao Y, Cobb MH. 2009. Regulation of a third conserved phosphorylation site in SGK1. J Biol Chem 284:3453–3460.
  • Cheng J, Zhang D, Kim K, Zhao Y, Zhao Y, Su B. 2005. Mip1, an MEKK2-interacting protein, controls MEKK2 dimerization and activation. Mol Cell Biol 25:5955–5964.
  • Cheng SW, Fryer LG, Carling D, Shepherd PR. 2004. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279:15719–15722.
  • Chiang GG, Abraham RT. 2005. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280:25485–25490.
  • Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. 2008. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105:17414–17419.
  • Copp J, Manning G, Hunter T. 2009. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69:1821–1827.
  • Dames SA, Mulet JM, Rathgeb-Szabo K, Hall MN, Grzesiek S. 2005. The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J Biol Chem 280:20558–20564.
  • Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ. 2002. PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J Biol Chem, 11, 11.
  • Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 12:295–303.
  • Dennis PB, Pullen N, Kozma SC, Thomas G. 1996. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 16:6242–6251.
  • DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. 2008. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22:239–251.
  • Dibble CC, Asara JM, Manning BD. 2009. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29:5657–5670.
  • Dong LQ, Liu F. 2005. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab 289:E187–E196.
  • Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. 2006. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314:467–471.
  • Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N. 2010. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328:1172–1176.
  • Dunlop EA, Hunt DK, Acosta-Jaquez HA, Fingar DC, Tee AR. 2011. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy 7:737–747.
  • Dunlop EA, Tee AR. 2009. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal 21:827–835.
  • Ekim B, Magnuson B, Acosta-Jaquez HA, Keller JA, Feener EP, Fingar DC. 2011. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol 31:2787–2801.
  • Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG. 1995. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem 270:987–990.
  • Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Martelli AM. 2011. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25:781–791.
  • Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, Sessa WC, Qin J, Zhang P, Su B, Jacinto E. 2008. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27:1932–1943.
  • Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. 2009. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal 2:ra4.
  • Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38.
  • Fenton TR, Gout IT. 2011. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43:47–59.
  • Fingar DC, Blenis J. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151–3171.
  • Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Soliman GA, Carriere A, Roux PP, Ballif BA, Fingar DC. 2010. Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J Biol Chem 285:80–94.
  • Frame S, Cohen P. 2001. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359:1–16.
  • Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865–1870.
  • Fujita N, Sato S, Ishida A, Tsuruo T. 2002. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 277:10346–10353.
  • Gao D, Wan L, Inuzuka H, Berg AH, Tseng A, Zhai B, Shaik S, Bennett E, Tron AE, Gasser JA, Lau A, Gygi SP, Harper JW, DeCaprio JA, Toker A, Wei W. 2010. Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol Cell 39:797–808.
  • Gao T, Newton AC. 2002. The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem 277:31585–31592.
  • García-Martínez JM, Alessi DR. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375–385.
  • Ghosh D, Srivastava GP, Xu D, Schulz LC, Roberts RM. 2008. A link between SIN1 (MAPKAP1) and poly(rC) binding protein 2 (PCBP2) in counteracting environmental stress. Proc Natl Acad Sci USA 105:11673–11678.
  • Gold MG, Barford D, Komander D. 2006. Lining the pockets of kinases and phosphatases. Curr Opin Struct Biol 16:693–701.
  • Gould CM, Kannan N, Taylor SS, Newton AC. 2009. The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. J Biol Chem 284:4921–4935.
  • Grosso S, Volta V, Sala LA, Vietri M, Marchisio PC, Ron D, Biffo S. 2008a. PKCbetaII modulates translation independently from mTOR and through RACK1. Biochem J 415:77–85.
  • Grosso S, Volta V, Vietri M, Gorrini C, Marchisio PC, Biffo S. 2008b. Eukaryotic ribosomes host PKC activity. Biochem Biophys Res Commun 376:65–69.
  • Gual P, Le Marchand-Brustel Y, Tanti JF. 2005. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99–109.
  • Guertin DA, Sabatini DM. 2009. The pharmacology of mTOR inhibition. Sci Signal 2:pe24.
  • Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. 2009. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15:148–159.
  • Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11:859–871.
  • Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214–226.
  • Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, Rothblum L, Moss T, Poortinga G, McArthur GA, Pearson RB, Hannan RD. 2003. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 23:8862–8877.
  • Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177–189.
  • Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213–223.
  • Hauge C, Antal TL, Hirschberg D, Doehn U, Thorup K, Idrissova L, Hansen K, Jensen ON, Jørgensen TJ, Biondi RM, Frödin M. 2007. Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation. EMBO J 26:2251–2261.
  • Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, Hardie DG. 2003. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28.
  • Hiraoka D, Okumura E, Kishimoto T. 2011. Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt. Oncogene.
  • Holz MK, Blenis J. 2005. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280:26089–26093.
  • Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. 2008. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30:701–711.
  • Horejsí Z, Takai H, Adelman CA, Collis SJ, Flynn H, Maslen S, Skehel JM, de Lange T, Boulton SJ. 2010. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol Cell 39:839–850.
  • Hresko RC, Mueckler M. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406–40416.
  • Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332:1317–1322.
  • Huang J, Manning BD. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179–190.
  • Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. 2008. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27:1919–1931.
  • Inoki K, Li Y, Xu T, Guan KL. 2003a. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829–1834.
  • Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657.
  • Inoki K, Zhu T, Guan KL. 2003b. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590.
  • Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125–137.
  • Jacinto E, Hall MN. 2003. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117–126.
  • Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. 2010. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16:205–213.
  • Jastrzebski K, Hannan KM, House CM, Hung SS, Pearson RB, Hannan RD. 2011. A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. Cell Signal 23:1338–1347.
  • Jiang T, Qiu Y. 2003. Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 278:15789–15793.
  • Johnstone CN, Castellví-Bel S, Chang LM, Sung RK, Bowser MJ, Piqué JM, Castells A, Rustgi AK. 2005. PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas. Genomics 85:338–351.
  • Joung SM, Park ZY, Rani S, Takeuchi O, Akira S, Lee JY. 2011. Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. J Immunol 186:499–507.
  • Julien LA, Carriere A, Moreau J, Roux PP. 2010. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30:908–921.
  • Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, Iemura S, Natsume T, Mizushima N. 2010. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem 285:20109–20116.
  • Kamada Y, Fujioka Y, Suzuki NN, Inagaki F, Wullschleger S, Loewith R, Hall MN, Ohsumi Y. 2005. Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol Cell Biol 25:7239–7248.
  • Kannan N, Haste N, Taylor SS, Neuwald AF. 2007. The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci USA 104:1272–1277.
  • Katajisto P, Vallenius T, Vaahtomeri K, Ekman N, Udd L, Tiainen M, Mäkelä TP. 2007. The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta 1775:63–75.
  • Keshwani MM, von Daake S, Newton AC, Harris TK, Taylor SS. 2011. Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1). J Biol Chem 286:23552–23558.
  • Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175.
  • Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM. 2003. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11:895–904.
  • Kobayashi T, Cohen P. 1999. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J 339 (Pt 2):319–328.
  • Kobayashi T, Deak M, Morrice N, Cohen P. 1999. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem J 344 Pt 1:189–197.
  • Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF. 2004. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67:1–10.
  • Lang F, Böhmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. 2006. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 86:1151–1178.
  • Langlais P, Yi Z, Mandarino LJ. 2011. The identification of raptor as a substrate for p44/42 MAPK. Endocrinology 152:1264–1273.
  • Laplante M, Sabatini DM. 2009. mTOR signaling at a glance. J Cell Sci 122:3589–3594.
  • Lazorchak AS, Liu D, Facchinetti V, Di Lorenzo A, Sessa WC, Schatz DG, Su B. 2010. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol Cell 39:433–443.
  • Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, Magnuson MA, Boothby M. 2010. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32:743–753.
  • Leitges M, Plomann M, Standaert ML, Bandyopadhyay G, Sajan MP, Kanoh Y, Farese RV, Letiges M. 2002. Knockout of PKC alpha enhances insulin signaling through PI3K. Mol Endocrinol 16:847–858.
  • Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D, Bezombes C. 2008. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 111:285–291.
  • Li Y, Soos TJ, Li X, Wu J, Degennaro M, Sun X, Littman DR, Birnbaum MJ, Polakiewicz RD. 2004. Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). J Biol Chem 279:45304–45307.
  • Liberman Z, Plotkin B, Tennenbaum T, Eldar-Finkelman H. 2008. Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue. Am J Physiol Endocrinol Metab 294:E1169–E1177.
  • Liu X, Zheng XF. 2007. Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol Biol Cell 18:1073–1082.
  • Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457–468.
  • Lovejoy CA, Cortez D. 2009. Common mechanisms of PIKK regulation. DNA Repair (Amst) 8:1004–1008.
  • Lu M, Wang J, Jones KT, Ives HE, Feldman ME, Yao LJ, Shokat KM, Ashrafi K, Pearce D. 2010. mTOR complex-2 activates ENaC by phosphorylating SGK1. J Am Soc Nephrol 21:811–818.
  • Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179–193.
  • Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318.
  • Ma XM, Yoon SO, Richardson CJ, Jülich K, Blenis J. 2008. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 133:303–313.
  • Makino C, Sano Y, Shinagawa T, Millar JB, Ishii S. 2006. Sin1 binds to both ATF-2 and p38 and enhances ATF-2-dependent transcription in an SAPK signaling pathway. Genes Cells 11:1239–1251.
  • Manning BD, Cantley LC. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 28:573–576.
  • Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261–1274.
  • Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002a. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151–162.
  • Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002b. The protein kinase complement of the human genome. Science 298:1912–1934.
  • Martin J, Masri J, Bernath A, Nishimura RN, Gera J. 2008. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun 372:578–583.
  • Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. 2007. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67:11712–11720.
  • McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ, Dedhar S. 2008. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68:1618–1624.
  • Messerschmidt A, Macieira S, Velarde M, Bädeker M, Benda C, Jestel A, Brandstetter H, Neuefeind T, Blaesse M. 2005. Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352:918–931.
  • Moeschel K, Beck A, Weigert C, Lammers R, Kalbacher H, Voelter W, Schleicher ED, Häring HU, Lehmann R. 2004. Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem 279:25157–25163.
  • Moser BA, Dennis PB, Pullen N, Pearson RB, Williamson NA, Wettenhall RE, Kozma SC, Thomas G. 1997. Dual requirement for a newly identified phosphorylation site in p70s6k. Mol Cell Biol 17:5648–5655.
  • Mukhopadhyay NK, Price DJ, Kyriakis JM, Pelech S, Sanghera J, Avruch J. 1992. An array of insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the p70 S6 kinase. J Biol Chem 267:3325–3335.
  • Nawaratne R, Gray A, Jørgensen CH, Downes CP, Siddle K, Sethi JK. 2006. Regulation of insulin receptor substrate 1 pleckstrin homology domain by protein kinase C: role of serine 24 phosphorylation. Mol Endocrinol 20:1838–1852.
  • Newton AC. 2003. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 370:361–371.
  • Newton AC. 2010. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 298:E395–E402.
  • Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. 1997. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem 272:952–960.
  • Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, Roux PP, Su B, Jacinto E. 2010. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J 29:3939–3951.
  • Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N, Maeda T. 2008. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 283:31861–31870.
  • Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, Brekken R, Wurz R, Tasker A, Polverino T, Tan SL, White MA. 2011. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 41:458–470.
  • Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, Hotamisligil GS. 2008. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29:541–551.
  • Panasyuk G, Nemazanyy I, Zhyvoloup A, Filonenko V, Davies D, Robson M, Pedley RB, Waterfield M, Gout I. 2009. mTORbeta splicing isoform promotes cell proliferation and tumorigenesis. J Biol Chem 284:30807–30814.
  • Parekh D, Ziegler W, Yonezawa K, Hara K, Parker PJ. 1999. Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem 274:34758–34764.
  • Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. 1999. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 18:3024–3033.
  • Partovian C, Ju R, Zhuang ZW, Martin KA, Simons M. 2008. Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells. Mol Cell 32:140–149.
  • Paz K, Liu YF, Shorer H, Hemi R, LeRoith D, Quan M, Kanety H, Seger R, Zick Y. 1999. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 274:28816–28822.
  • Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR. 2007. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405:513–522.
  • Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, Thomas G. 1995. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 14:5279–5287.
  • Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G. 2004. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112–3124.
  • Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S. 2001. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276:27462–27469.
  • Peterson RT, Beal PA, Comb MJ, Schreiber SL. 2000. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 275:7416–7423.
  • Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873–886.
  • Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA, Hall MN. 2008. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 8:399–410.
  • Polak P, Hall MN. 2009. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21:209–218.
  • Proud CG. 2007. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 403:217–234.
  • Pullen N, Thomas G. 1997. The modular phosphorylation and activation of p70s6k. FEBS Lett 410:78–82.
  • Qian SB, Zhang X, Sun J, Bennink JR, Yewdell JW, Patterson C. 2010. mTORC1 links protein quality and quantity control by sensing chaperone availability. J Biol Chem 285:27385–27395.
  • Ramírez-Rangel I, Bracho-Valdés I, Vázquez-Macías A, Carretero-Ortega J, Reyes-Cruz G, Vázquez-Prado J. 2011. Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57. Mol Cell Biol 31:1657–1671.
  • Ramírez-Valle F, Badura ML, Braunstein S, Narasimhan M, Schneider RJ. 2010. Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation. Mol Cell Biol 30:3151–3164.
  • Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, Polakiewicz RD, Sonenberg N, Hershey JW. 2004. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23:1761–1769.
  • Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ. 2009. Protein kinase C intervention: the state of play. Curr Opin Cell Biol 21:268–279.
  • Romanelli A, Dreisbach VC, Blenis J. 2002. Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem 277:40281–40289.
  • Romanelli A, Martin KA, Toker A, Blenis J. 1999. p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol 19:2921–2928.
  • Rosner M, Freilinger A, Hengstschläger M. 2006. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat Res 613:10–16.
  • Rosner M, Freilinger A, Hengstschläger M. 2007. Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene 26:521–531.
  • Rosner M, Hengstschläger M. 2008. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 17:2934–2948.
  • Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. 2010. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 11:103–112.
  • Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. 2004. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101:13489–13494.
  • Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J. 2007. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282:14056–14064.
  • Ruvinsky I, Meyuhas O. 2006. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31:342–348.
  • Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G. 2002. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 277:20104–20112.
  • Sakoda H, Gotoh Y, Katagiri H, Kurokawa M, Ono H, Onishi Y, Anai M, Ogihara T, Fujishiro M, Fukushima Y, Abe M, Shojima N, Kikuchi M, Oka Y, Hirai H, Asano T. 2003. Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J Biol Chem 278:25802–25807.
  • Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. 2007. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117:739–745.
  • Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290–303.
  • Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496–1501.
  • Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25:903–915.
  • Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, Williams MR, Morrice N, Deak M, Alessi DR. 2001. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. J Biol Chem 276:19469–19482.
  • Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302.
  • Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168.
  • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101.
  • Sarbassov DD, Sabatini DM. 2005. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 280:39505–39509.
  • Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. 2003. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 5:566–571.
  • Schalm SS, Blenis J. 2002. Identification of a conserved motif required for mTOR signaling. Curr Biol 12:632–639.
  • Schalm SS, Tee AR, Blenis J. 2005. Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. J Biol Chem 280:11101–11106.
  • Schleich S, Teleman AA. 2009. Akt phosphorylates both Tsc1 and Tsc2 in Drosophila, but neither phosphorylation is required for normal animal growth. PLoS ONE 4:e6305.
  • Schroder W, Bushell G, Sculley T. 2005. The human stress-activated protein kinase-interacting 1 gene encodes JNK-binding proteins. Cell Signal 17:761–767.
  • Schroder WA, Buck M, Cloonan N, Hancock JF, Suhrbier A, Sculley T, Bushell G. 2007. Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. Cell Signal 19:1279–1289.
  • Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504–3513.
  • Shah OJ, Hunter T. 2004. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J Biol Chem 279:20816–20823.
  • Shah OJ, Hunter T. 2006. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 26:6425–6434.
  • Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. 2006. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25:2781–2791.
  • Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91–99.
  • Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA. 2006. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11:583–589.
  • Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC. 2010. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285:7866–7879.
  • Sonenberg N, Hinnebusch AG. 2009. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136:731–745.
  • Sonnenburg ED, Gao T, Newton AC. 2001. The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide 3-kinase. J Biol Chem 276:45289–45297.
  • Standaert ML, Bandyopadhyay G, Galloway L, Soto J, Ono Y, Kikkawa U, Farese RV, Leitges M. 1999. Effects of knockout of the protein kinase C beta gene on glucose transport and glucose homeostasis. Endocrinology 140:4470–4477.
  • Sun Y, Chen J. 2008. mTOR signaling: PLD takes center stage. Cell Cycle 7:3118–3123.
  • Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA, Chen J. 2008. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci USA 105:8286–8291.
  • Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T. 2006. Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J Biol Chem 281:28605–28614.
  • Takai H, Wang RC, Takai KK, Yang H, de Lange T. 2007. Tel2 regulates the stability of PI3K-related protein kinases. Cell 131:1248–1259.
  • Takai H, Xie Y, de Lange T, Pavletich NP. 2010. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev 24:2019–2030.
  • Taniguchi CM, Emanuelli B, Kahn CR. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85–96.
  • Tao Z, Barker J, Shi SD, Gehring M, Sun S. 2010. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes. Biochemistry 49:8488–8498.
  • Tato I, Bartrons R, Ventura F, Rosa JL. 2011. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem 286:6128–6142.
  • Taylor SS, Kim C, Cheng CY, Brown SH, Wu J, Kannan N. 2008. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim Biophys Acta 1784:16–26.
  • Tessier M, Woodgett JR. 2006. Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem 98:1391–1407.
  • Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jenö P, Arrieumerlou C, Hall MN. 2007. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2:e1217.
  • Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023–8032.
  • Treins C, Warne PH, Magnuson MA, Pende M, Downward J. 2010. Rictor is a novel target of p70 S6 kinase-1. Oncogene 29:1003–1016.
  • Tremblay F, Brûlé S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, Marette A. 2007. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 104:14056–14061.
  • Tzatsos A, Kandror KV. 2006. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26:63–76.
  • Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205.
  • Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9:316–323.
  • Viniegra JG, Martínez N, Modirassari P, Losa JH, Parada Cobo C, Lobo VJ, Luquero CI, Alvarez-Vallina L, Ramón y Cajal S, Rojas JM, Sánchez-Prieto R. 2005. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 280:4029–4036.
  • Wang L, Lawrence JC Jr, Sturgill TW, Harris TE. 2009. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J Biol Chem 284:14693–14697.
  • Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. 2001. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20:4370–4379.
  • Wang X, Proud CG. 2009. Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol 19:260–267.
  • Waraich RS, Weigert C, Kalbacher H, Hennige AM, Lutz SZ, Häring HU, Schleicher ED, Voelter W, Lehmann R. 2008. Phosphorylation of Ser357 of rat insulin receptor substrate-1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells. J Biol Chem 283:11226–11233.
  • Weng QP, Andrabi K, Kozlowski MT, Grove JR, Avruch J. 1995. Multiple independent inputs are required for activation of the p70 S6 kinase. Mol Cell Biol 15:2333–2340.
  • Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH. 2007. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 282:25604–25612.
  • Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. 2003. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004–2008.
  • Wu YT, Ouyang W, Lazorchak AS, Liu D, Shen HM, Su B. 2011. mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif. J Biol Chem 286:14190–14198.
  • Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell 124:471–484.
  • Wullschleger S, Loewith R, Oppliger W, Hall MN. 2005. Molecular organization of target of rapamycin complex 2. J Biol Chem 280:30697–30704.
  • Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, Wang CY, Guan KL. 2011. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 108:6474–6479.
  • Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA, Barford D. 2002. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9:1227–1240.
  • Yang Q, Inoki K, Ikenoue T, Guan KL. 2006. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20:2820–2832.
  • Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. 2010. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38:768–774.
  • Yoshida S, Hong S, Suzuki T, Nada S, Mannan AM, Wang J, Okada M, Guan KL, Inoki K. 2011. Redox regulates mTORC1 activity by modulating the TSC1/TSC2-Rheb pathway. J Biol Chem 286:32651–32660.
  • Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A. 2009. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69:6232–6240.
  • Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, Blenis J. 2011. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322–1326.
  • Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. 2006b. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24:185–197.
  • Zhang Y, Billington CJ Jr, Pan D, Neufeld TP. 2006b. Drosophila target of rapamycin kinase functions as a multimer. Genetics 172:355–362.
  • Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. 2009. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33:237–247.
  • Zinzalla V, Stracka D, Oppliger W, Hall MN. 2011. Activation of mTORC2 by association with the ribosome. Cell 144:757–768.
  • Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21–35.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.